Index

Note: Page numbers in italics refer to Figures.

acamprosate
  as adjunctive therapy, 32
  alcohol dependence, 31–33, 33
  mechanism of action, 31, 46
  naltrexone vs., 32
  pregnancy, 49
  psychosocial treatments and, 32
adolescents
  mentoring, substance use disorders prevention, 10–11, 11
  opiate-dependent see opiate-dependent adolescents
  see also young people
agonist maintenance treatments, opioid dependence, 94–95
  psychosocial treatment and, 94–95
alcohol and other substance use disorders (AOD), case management, 56
Alcohol Craving Scale, gamma-hydroxybutyrate, 37
alcohol dependence
  acamprosate, 31–33, 33
  opioid antagonists, 46–48, 48
  Twelve Step Facilitation programmes, 8–9
  Alcoholics Anonymous (AA), 8
  addiction severity, 9
  alcohol dependence, 8–9
  alcohol misuse
    university/college students, social norms interventions, 19–21, 21
    young people see young people
  alcohol withdrawal
    anticonvulsants, 27–30, 29
    baclofen, 34–35
    benzodiazepines, 40
    gamma-hydroxybutyrate, 36–39
    pharmacological interventions efficacy, 43–45
    safety, 43–45
    psychotropic analgesic nitrous oxide, 40–42
  alpha-2-adrenergic agonists
    buprenorphine vs., 100
    methadone vs., 97
    opioid antagonists and, 115, 116
    opioid withdrawal, 96–98, 98
Alternative Program for Methadone Maintenance Treatment Program (MMTP), 90
amantadine, cocaine dependence, 79
antidepressants vs., 79
aminetpine, 147, 148
amlodipine, 145–146
amphetamine dependence/use, 145–146, 147
amphetamine psychosis treatment, 149–150
amphetamines, 145
  psychotic symptoms, 149
amphetamine withdrawal, 147–148
  future developments, 148
  antagonist-induced withdrawal, 114
anticonvulsants
  alcohol withdrawal, 27–30, 29
  antidepressants vs., 72
  benzodiazepines vs., 28, 44
  cocaine dependence, 72, 76–77
  efficacy, 45
  safety, 45
antidepressants
  amantadine, 79
  anticonvulsants vs., 72
  benzodiazepine dependence, 144
  cocaine dependence, 71–73
  depression during opioid agonist treatment, 136, 137
  dopamine agonists vs., 72
  pregnancy, 49
  problematic cocaine use, 71–73
antipsychotics
  benzodiazepines vs., 44
  cocaine dependence, 74–75
  antipsychotics vs., 44
  delirium, 25
  efficacy, 45
  fixed-schedule vs. symptom-triggered, 25
  gamma-hydroxybutyrate vs., 36
  naltrexone vs., 119
  placebo vs., 25, 26, 44
  pregnancy, 49
  psychotropic analgesic nitrous oxide vs., 41, 42
  safety, 45
  seizures, 24, 25, 26, 44, 45
  short vs. long half-life, 143

© 2012 John Wiley & Sons, Ltd. Published 2012 by John Wiley & Sons, Ltd.
Index

binge drinking
social norms interventions, 20
universal school-based prevention
programmes, 12, 14
blood alcohol content, university/college students, 20
brief alcohol interventions
definition, 5
gender differences, 2
heavy users, general hospital wards, 5–7, 7
primary care populations, 1–4, 3
Brief Reinforcement Based Intensive Outpatient Therapy coupled with Contingency Management, opiate dependence, 90
bromocriptine, 79
buprenorphine
alpha2-adrenergic agonists vs., 100, 101
efficacy, 103
future research, 100
maintenance therapy, 102–104, 104
methadone vs., 99, 100, 101, 102–104
naloxone vs., 119
newborns, 134
opiate-dependent adolescents, 130, 131–132
opiate-dependent pregnant women, 134
opioid dependence, 102–104, 104
opioid detoxification, 92
opioid withdrawal, 99–101, 114
psychosocial treatment vs., 92
buprenorphine–naloxone, 130, 131–132
buspirone, 143
cannabis use/dependence, 140
family interventions, 55
motivational interviews, 55
outpatient psychotherapeutic interventions, 140–141
psychotherapeutic interventions, 141
young people, 55
carbamazepine
alcohol withdrawal, 28
benzodiazepine dependence, 142, 144
benzodiazepines vs., 28
Carbidopa, 79
case management
drug counselling vs., 57
illicit substance use disorders, 56, 58
psycho-education vs., 57
substance use disorders, 56–58
chloral hydrate, 28
chlor Diazepoxide, 25, 28, 44
chlorzoxazone
gamma-hydroxybutyrate vs., 36, 37, 38, 39
pregnancy, 49
chlorpromazine, amphetamine psychosis, 149
Clinical Institute Withdrawal Assessment of Alcohol Scale – Revised (CIWA-Ar), 25, 28, 34, 35, 39, 43
clofemethaolox see clomethoiazo lime
clonidine
adverse effects, 99
buprenorphine vs., 100, 101, 130
methadone vs., 97
opiate-dependent adolescents, 130
opioid antagonists and, 115, 116
opioid withdrawal, 96, 97, 99
cocaine abstinence, methadone maintenance, 109
cocaine dependence
anticonvulsants, 72, 76–77
antidepressants, 71–73
antipsychotics, 74–75
dopamine agonists, 72, 78–81, 80
cocaine use, problematic, antidepressants and, 71–73
cognitive-behavioural therapy (CBT)
cannabis use/dependence, 141
cocaine related disorders, 70
psychostimulant amphetamine related disorders, 70
college students, social norms interventions, 19–21, 21
community-setting interventions
drug-using offenders, 64–65
young people, substance use disorders, 55
computer-delivered interventions, university/college students, 20
contingency management (CM)
cocaine related disorders, 70
opiate dependence, 90
pregnant illicit drug users, 67, 68
psychostimulant amphetamine related disorders, 70
counselling, cannabis use/dependence, 141
Cue Exposure therapy, opiate dependence, 90
delirium
benzodiazepines, 25
opioid antagonists, 116
depression, opioid agonist treatments, 135–137, 137
desipramine
amphetamine dependence/use, 145–146
cocaine dependence, 72, 73
problematic cocaine use, 72
detoxification, 105
diazepam, baclofen vs., 35
disulfiram
cocaine dependence, 82–83
gamma-hydroxybutyrate vs., 36, 37, 38, 39
mechanism of action, 82
naloxone vs., 83
pregnancy, 49
dopamine agonists, cocaine dependence, 72, 78–81, 80
antidepressants vs., 72
dopamine antagonists, 149
dopamine transmission manipulation, 78
dothiepin, 143
drinking frequency, university/college students, 20
drinking quantity, university/college students, 20
drug counselling, case management vs., 57
drug-using offenders
community-based interventions, 64–65
court interventions, 64–65
intensive supervision, 65
interventions, 64–65, 65
secure establishment interventions, 64–65
therapeutic communities, 65
drunkenness, universal school-based prevention programmes, 12, 14
Enhanced Outreach-Counselling Program, opiate dependence, 90
escitalopram, gamma-hydroxybutyrate and, 37
family interventions, substance use disorders, 55
flumazenil, 144
fluoxetine, 145–146
foetal alcohol syndrome interventions, 23
Index 155

gabapentin, cocaine dependence, 77
gamma-hydroxybutyrate (GHB), 38
  adverse effects, 36
  alcohol abstinence rate, 37
  alcohol withdrawal, 36–39
  benzodiazepines vs., 36, 38
  chlorpromazine vs., 36, 37, 38
  disulfiram vs., 36, 37, 38
  efficacy, 45
  escitalopram and, 37
  future developments, 38
  mechanism of action, 36
  naltrexone and, 37
  naltrexone vs., 36, 37, 38, 39
  relapse prevention, 36–39
  safety, 45
  side effects, 38
  Good Behaviour Game, 12, 13,
  hallucinations, cocaine use, 74
  haloperidol
    amphetamine psychosis, 149, 150
    cocaine dependence, 75
  heroin
    newborns, effects on, 133
    in pregnancy, 133
  heroin maintenance
    achievements, 123
    chronic heroin-dependent individuals, 123–125
    indications, 124
    methadone and, 123–124
    methadone vs., 125
    mortality rates, 124
    social functioning, 124
  hydroxyzine, benzodiazepine dependence, 143
  ‘illegal drugs,’ adolescent mentoring, 11
  illicit substance use disorders
    case management, 57, 58
    school-based prevention, 51–53, 53
  imipramine, amphetamine dependence/use, 145–146

LAAM maintenance
  adverse effects, 126, 127
  duration of action, 126
  heroin dependence, 126–128
  methadone maintenance vs., 126–128, 128
  opioid-dependent adolescents, 132
  Ldopa, cocaine dependence, 79
  levo-alpha-acetylmethadol (LAAM)
    maintenance see LAAM maintenance
  levodopa, cocaine dependence, 79
  Life Skills Training Program, 12, 14, 18
  lofexidine
    buprenorphine vs., 100
    methadone vs., 97
    opioid antagonists and, 115, 116
    opioid withdrawal, 96, 97
  lorazepam, 28
  managed withdrawal, 105
  mentoring, 10
  methadone (maintenance)
    adrenergic agonists vs., 106
    alpha-, adrenergic agonists vs., 97
    buprenorphine maintenance vs., 102–104, 104
    buprenorphine vs., 99, 100, 101
    criminal activity and, 111
  future trials, 109
  heroin maintenance and, 123–124, 125
  heroin maintenance vs., 125
  high doses, 108, 109
  LAAM maintenance vs., 126–128, 128
  low doses, 108, 109
  middle doses, 109
  newborns, 134
  no opioid replacement therapy vs., 110–112, 112
  opioid-dependent adolescents, 130, 132
  opioid-dependent pregnant women, 134
  opioid dependence, different doses, 108–109
  opioid detoxification, 92
  opioid withdrawal, tapered doses, 105–107, 106, 107
  psychosocial treatment vs., 92
  rapid tapering, 106
  methaqualone dependence treatment, 151–152
  mirtazapine, amphetamine withdrawal, 147, 148
  morphine, opioid-dependent pregnant women, 134
  motivational interviewing
    pregnant illicit drug users, 68
    substance use disorders, 59–61, 61
  young people, substance use disorders prevention, 54, 55
  multicomponent community interventions, substance use disorders, 55
  nalmefene, 47
  naloxone, opioid-dependent adolescents, 130, 131–132
  naltrexone
    acamprosate vs., 32
    adverse effects, 122
    benzodiazepines vs., 119
    buprenorphine vs., 119
    cocaine dependence, 83
    depot injections, 121, 122
    disulfiram vs., 83
    future trials, 119
    gamma-hydroxybutyrate and, 37
    gamma-hydroxybutyrate vs., 36, 37, 38
    implants, 121
    mechanism of action, 46
    opioid antagonists and, 114
    opioid dependence, 118–122
    oral maintenance treatment, 118–120, 120
    placebo vs., 47, 48, 122
    pregnancy, 49
    psychotherapy and, 119
    psychotherapy vs., 118
    side effects, 47
    sustained-release preparations, 118, 121–122
  normative feedback, 19
  olanzapine
    amphetamine psychosis, 149, 150
    cocaine dependence, 75
  opioid-dependent adolescents
    detoxification treatments, 129–130
    maintenance treatments, 131–132
  opioid-dependent pregnant women
    buprenorphine, 134
    maintenance agonist treatments, 133–134
    methadone, 134
  opioid antagonists
    adjunct medication, 115
    adverse effects, 113, 114
    alcohol dependence, 46–48, 48
    alpha-, adrenergic agonists and, 115, 116
    anaesthesia duration, 114
Index

156

controversy over, 113
delirium, 116
under heavy sedation/anaesthesia, 113–114
methadone vs., 106
with minimal sedation, 115–117
future studies, 116
methodological quality issues, 116, 117
naltrexone and, 114
opioid withdrawal, 113–117
opioid dependence
depression during opioid agonist treatment, 135–137, 137
detoxification, inpatient vs. other settings, 138–139
psychosocial treatment, 89–90
relapse post-detoxification, 96
withdrawal, 96
opioid withdrawal, alpha-2-adrenergic agonists, 96–98, 98
outpatient detoxification, opioid dependence, 139
oxazepam, 28
paraldehyde, 28
paranoia, cocaine use, 74
peer influence, substance use disorders, 62
phenothiazines, pregnancy, 49
phenytoin
alcohol withdrawal, 29
cocaine dependence, 77
pregnancy
alcohol consumption effects, 49
alcohol interventions, 22–23, 49–50
illicit drug use, 67
opioid dependence see opiate-dependent pregnant women
outpatient illicit drug treatment programmes, 67–68
pharmacologic interventions, 49–50
psychosocial interventions, 22–23, 67–68
primary care populations, brief alcohol interventions, 1–4, 3
primary intervention, 51
prison setting therapeutic communities, substance use disorders, 63
progesterone, benzodiazepine dependence, 143
propranolol, benzodiazepine dependence, 143
psycho-education, case management vs., 57
psychosocial interventions
alcohol consumption in pregnancy, 22–23
cocaine related disorders, 69–70
outpatient illicit drug treatment programmes in pregnancy, 67–68
psychostimulant amphetamine related disorders, 69–70
psychosocial treatment
opioid dependence, 89–90
agonist maintenance treatments and, 94–95
agonist maintenance treatments vs., 94–95
opioid detoxification
pharmacological treatment and, 91–93, 93
pharmacological treatment vs., 93
pharmacological vs., 91–93
psychostimulant amphetamine related disorders, 69–70
psychostimulant dependence, 69
psychostimulant drugs, cocaine dependence
efficacy, 84–86
placebo vs., 85, 86
psychotropic analgesic nitrous oxide (PAN) alcoholic withdrawal states, 40–42
benzodiazepines vs., 41, 42
cost-effectiveness, 41
quinazoline, 151
risperidone, cocaine dependence, 75, 75
school-based prevention, illicit substance use disorders, 51–53
affective interventions, 52
knowledge-focused programmes, 52, 53
skills-based interventions, 52
seizures, benzodiazepines, 24, 25, 26, 44, 45
social norms, 19
social norms interventions, alcohol misuse reduction in university/college students, 19–21
social skills, illicit substance use disorders, 52
substance use disorders
adolescent mentoring, 10–11, 11
motivational interviewing, 59–61, 61
peer influence, 62
therapeutic communities, 62–63
therapeutic communities (TC)
community residence vs., 63
drug-using offenders, 64, 65
within prison setting, 63
standard vs. enhanced abbreviated, 63
substance use disorders, 62–63
thioridazine, amphetamine psychosis, 149
tricyclic antidepressants
cocaine dependence, 72
depression during opioid agonist treatment, 136
problematic cocaine use, 72
Twelve Step Facilitation (TSF) programmes
addiction severity, 9
alcohol dependence, 8–9
universal family-based prevention programmes, alcohol misuse, 17–18
universal multicomponent prevention programmes, alcohol misuse in young people, 15–16
universal prevention, aims, 12
universal school-based prevention programmes, alcohol misuse, 12–14, 17–18
university students, social norms interventions, 19–21
Unplugged programme, 12, 13
voucher-based incentives, cannabis use/dependence, 141
web-delivered interventions, university/college students, 20
young people
alcohol misuse
multiple vs. single-component interventions, 16
universal family-based prevention programmes, 17–18
universal multicomponent prevention programmes, 15–16
universal school-based prevention programmes, 12–14, 17–18
substance use disorders prevention, non-school setting, 54–55